Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK

Nuclear Medicine and Biology

Volumn 36, Issue 6, 2009, Pages 671-680

  Vaidyanathan, Ganesan ^a   Jestin, Emmanuelle ^a   Olafsen, Tove ^b   Wu, Anna M ^b   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HER2; Internalization; Monoclonal antibody; Radioiodination

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; N EPSILON 3 IODOBENZOYL 5 LYSINE N ALPHA MALEIMIDO 1 GLYCINE GEEEK I 131; N SUCCINIMIDYL 4 GUANIDINOMETHYL 3 IODOBENZOATE I 131; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FV FC FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOIODINATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BENZOATES; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANIDINE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IODINE RADIOISOTOPES; MICE; MUTATION; OLIGOPEPTIDES; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 67651162035     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.04.002     Document Type: Article

References (46)

1. Ferretti G., Felici A., Papaldo P., Fabi A., and Cognetti F. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19 (2007) 56-62
2. Morris S.R., and Carey L.A. Trastuzumab and beyond: new possibilities for the treatment of HER2-positive breast cancer. Oncology (Huntingt) 20 (2006) 1763-1771
3. Nahta R., and Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 26 (2007) 3637-3643
4. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89 (1992) 4285-4289
5. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357 (2007) 39-51
6. Torigian D.A., Huang S.S., Houseni M., and Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 57 (2007) 206-224
7. da Silva F.A., Corte-Real S., and Goncalves J. Recombinant antibodies as therapeutic agents - Pathways for modeling new biodrugs. Biodrugs 22 (2008) 301-314
8. Demarest S.J., and Glaser S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Dev 11 (2008) 675-687
9. Hu S., Shively L., Raubitschek A., Sherman M., Williams L.E., Wong J.Y., et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56 (1996) 3055-3061
10. Yazaki P.J., Wu A.M., Tsai S.W., Williams L.E., Ikler D.N., Wong J.Y., et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem 12 (2001) 220-228
11. Olafsen T., Kenanova V.E., Sundaresan G., Anderson A.L., Crow D., Yazaki P.J., et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65 (2005) 5907-5916
12. Kenanova V., Olafsen T., Crow D.M., Sundaresan G., Subbarayan M., Carter N.H., et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65 (2005) 622-631
13. Brambell F.W. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 2 (1966) 1087-1093
14. Junghans R.P., and Anderson C.L. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93 (1996) 5512-5516
15. Kim J.K., Firan M., Radu C.G., Kim C.H., Ghetie V., and Ward E.S. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 29 (1999) 2819-2825
16. Austin C.D., Wen X., Gazzard L., Nelson C., Scheller R.H., and Scales S.J. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci USA 102 (2005) 17987-17992
17. Mittendorf E.A., Storrer C.E., Shriver C.D., Ponniah S., and Peoples G.E. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13 (2006) 1085-1098
18. 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 33 (2006) 333-347
19. Borchardt P.E., Yuan R.R., Miederer M., McDevitt M.R., and Scheinberg D.A. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 63 (2003) 5084-5090
20. Kobayashi H., Shirakawa K., Kawamoto S., Saga T., Sato N., Hiraga A., et al. Rapid accumulation and internalization of radiolabeled Herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256). Cancer Res 62 (2002) 860-866
21. 111In-Labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 48 (2007) 1357-1368
22. Olafsen T., Cheung C.W., Yazaki P.J., Li L., Sundaresan G., Gambhir S.S., et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 17 (2004) 21-27
23. 131I for use in radioimmunotherapy. J Nucl Med 46 (2005) 153-159
24. Stein R., Govindan S.V., Hayes M., Griffiths G.L., Hansen H.J., Horak I.D., et al. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody. Clin Cancer Res 11 (2005) 2727-2734
25. Vaidyanathan G., Affleck D.J., Bigner D.D., and Zalutsky M.R. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 29 (2002) 1-11
26. 211At. Nucl Med Biol 30 (2003) 351-359
27. 1-GEEEK ([*I]IB-Mal-d-GEEEK): a radioiodinated prosthetic group containing negatively charged d-glutamates for labeling internalizing monoclonal antibodies. Bioconjug Chem 17 (2006) 1085-1092
28. Vaidyanathan G., and Zalutsky M.R. Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides. Nat Protoc 2 (2007) 282-286
29. Benz C.C., Scott G.K., Sarup J.C., Johnson R.M., Tripathy D., Coronado E., et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24 (1992) 85-95
30. 131I]SGMIB). Bioconjug Chem 12 (2001) 428-438
31. Brooks S.C., Hansen E.R., Saunders D.E., Battelli M.G., and Shafie S.M. Effect of growth on the estrogen receptor levels in MCF-7 cells. Cancer Res 44 (1984) 3724-3729
32. DeNardo G.L., DeNardo S.J., Peterson J.J., Miers L.A., Lam K.S., Hartmann-Siantar C., et al. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin Cancer Res 9 (2003) 3865S-3872S
33. 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. Clin Cancer Res 5 (1999) 533-541
34. Kukis D.L., DeNardo G.L., DeNardo S.J., Mirick G.R., Miers L.A., Greiner D.P., et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 55 (1995) 878-884
35. 64Cu-BAT-2IT-1A3. Cancer Biother Radiopharm 16 (2001) 483-494
36. Foulon C.F., Reist C.J., Bigner D.D., and Zalutsky M.R. Radioiodination via d-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 60 (2000) 4453-4460
37. Maack T., Park C.H., and Camargo M.J. Filtration, transport, and metabolism of proteins. In: Seldin D.W., and Giebisch G. (Eds). Physiology and Pathophysiology (1992), Raven Press, New York 3005-3038
38. 177Lu-labeled α-melanocyte stimulating hormone peptide analogues. Nucl Med Biol 33 (2006) 723-733
39. 111In-labeled RGD peptide. Nucl Med Biol 34 (2007) 29-35
40. 1]-minigastrin. Bioconjug Chem 15 (2004) 864-871
41. Wen X., Jackson E.F., Price R.E., Kim E.E., Wu Q., Wallace S., et al. Synthesis and characterization of poly(l-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent. Bioconjug Chem 15 (2004) 1408-1415
42. Behe M., Kluge G., Becker W., Gotthardt M., and Behr T.M. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 46 (2005) 1012-1015
43. Gotthardt M., van Eerd-Vismale J., Oyen W.J., de Jong M., Zhang H., Rolleman E., et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 48 (2007) 596-601
44. Rexhepaj R., Grahammer F., Volkl H., Remy C., Wagner C.A., Sandulache D., et al. Reduced intestinal and renal amino acid transport in PDK1 hypomorphic mice. FASEB J 20 (2006) 2214-2222
45. Verrey F., Ristic Z., Romeo E., Ramadan T., Makrides V., Dave M.H., et al. Novel renal amino acid transporters. Annu Rev Physiol 67 (2005) 557-572
46. Kenanova V., Olafsen T., Williams L.E., Ruel N.H., Longmate J., Yazaki P.J., et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 67 (2007) 718-726